Lipid-lowering therapy and LDL target attainment in type 2 diabetes: trends from the Italian Associations of Medical Diabetologists database
Authors' conclusion
While LDL-c management in Italian patients with T2DM has improved, significant gaps remain, particularly for very high-risk individuals. Expanding the use of advanced therapies like PCSK9 inhibitors and adhering more closely to guideline-based recommendations are critical to improve cardiovascular risk in this population.
Study context
- Population
- Italian patients with T2D in the AMD Annals database, 2019–2022, stratified by cardiovascular risk
- Participants
- over 700,000 patients
- Outcome
- Trends in LDL-C target achievement and lipid-lowering treatment by cardiovascular risk
- Follow-up
- 2019 to 2022
Methodological detailsrepeated annual cross-sectional analyses 2019–2022, AMD Annals database
- Repeated annual cross-sectional analyses 2019–2022
- AMD Annals database
Main finding
As reported in the abstract
LDL-C target achievement
Very high risk, LDL-C < 55 mg/dL: 2019 vs 2022
16.3% vs 23.6%
High risk, LDL-C < 70 mg/dL: 2019 vs 2022
20.3 to 26.6%
Observational data: associations, not effects.
Further findings
Target achievement with PCSK9 inhibitors · 2022
- PCSK9 inhibitors, particularly with statins, associated with highest target achievement; very high risk by 2022
- 62%
Lipid-lowering therapy use · 2019 to 2022
- Reduced moderate-intensity statin use in favour of combination therapies
LDL-C ≥ 100 mg/dL · 2022
- Patients with LDL-C ≥ 100 mg/dL in 2022
- nearly one-third
Original publication
Lipid-lowering therapy and LDL target attainment in type 2 diabetes: trends from the Italian Associations of Medical Diabetologists database. Cardiovasc Diabetol. Published 28 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →